Researchers from the Icahn School of Medicine at Mount Sinai will present their Late-Breaking Clinical Trial findings and other important research results advancing the field of cardiovascular medicine at the American College of Cardiology's (ACC) 65th Annual Scientific Session and Expo in Chicago, from April 2 to 4. Mount Sinai Heart is ranked No. 7 in the nation by U.S. News & World Report in its 2015 "Best Hospitals" issue.
The new findings advance our scientific knowledge of:
- CABG alone or CABG and mitral valve repair as treatment strategies for moderate ischemic MR after two-years; and
- the use of rate versus rhythm control in patients with atrial fibrillation.
Significant embargoed scientific presentations include:
Embargoed: Sunday, April 3, 12:30 p.m. CDTJoint American College of Cardiology/New England Journal of Medicine Featured Clinical Research
Session 1-Session 406: Isch MR: Two-year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation: A Randomized Clinical Trial from The Cardiothoracic Surgical Trials Network
The study, which will be presented at ACC 2016 and published simultaneously online by the New England Journal of Medicine (NEJM), compares the two-year outcomes of treating patients with moderate ischemic MR with either coronary artery bypass grafting (CABG) alone or with both CABG and mitral valve repair. Annetine C. Gelijns, PhD, the Edmond A. Guggenheim Professor of Health Policy and Chair of the Department of Health Evidence and Policy at the Icahn School of Medicine at Mount Sinai, is the principal investigator for the Data Coordinating Center based at Mount Sinai for the NIH-sponsored Cardiothoracic Surgical Trials Network (CTSN), which conducted the clinical trial, and she is the corresponding author for the upcoming NEJM publication highlighting the results. The CTSN has eight core clinical centers, and Robert Michler, MD, Surgeon-in-Chief, Samuel I. Belkin Chair, Professor and Chairman, Department of Cardiothoracic and Vascular Surgery at Montefiore Health System, will present the research findings on behalf of the CTSN at ACC 2016.
Embargoed: Monday, April 4, 8:00 a.m.CDTJoint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trial
Session 410: Rate v Rhythm: A Randomized Trial of Rate Control Versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery
The study, which will be presented at ACC 2016 and published simultaneously online by the NEJM, compares the strategies of rate versus rhythm control in patients with postoperative atrial fibrillation (POAF) after cardiac surgery to help inform management strategies to mitigate the risks of adverse outcomes caused by POAF. Annetine C. Gelijns, PhD, the Edmond A. Guggenheim Professor of Health Policy and Chair of the Department of Health Evidence and Policy at the Icahn School of Medicine at Mount Sinai, is the principal investigator for the Data Coordinating Center based at Mount Sinai for the NIH-sponsored Cardiothoracic Surgical Trials Network (CTSN), which conducted the clinical trial, and she is the corresponding author for the upcoming NEJM publication highlighting the results. The CTSN has eight core clinical centers, and Marc Gillinov, MD, Cardiothoracic Surgeon, Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute, will present the research findings on behalf of the CTSN at ACC 2016.
Source: The Mount Sinai Hospital / Mount Sinai School of Medicine